Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials.

BMC Psychiatry · 2011 · PMC3152513 · PMID 21689438

Europe PMC DOI

hedged sentences

0.0840

closest p · 1.7× alpha

0.0890

boldest claim

The sentences

showed a trendP = 0.084so close (0.05 < p ≤ 0.1)

Change from baseline in MADRS total score with olanzapine was not statistically different from placebo at day 7 (-5.3 ± 0.9 vs -3.6 ± 1.4; P = 0.314), but it showed a trend towards statistical significance on day 21 (-8.8 ± 1.0 vs -5.4 ± 1.6; P = 0.084) (Figure 1B ).

also in 53,322 other papers

approached significanceP = 0.089so close (0.05 < p ≤ 0.1)

In patients with a mixed episode at baseline, LS mean ± SE changes in CGI-BP-D severity score with asenapine were significantly greater than placebo on day 7 (-0.7 ± 0.1 vs -0.3 ± 0.1; P = 0.008) and approached significance on day 21 (-1.0 ± 0.1 vs -0.7 ± 0.2; P = 0.089); asenapine and olanzapine did not differ on either day 7 ( P = 0.968) or 21 ( P = 0.543).

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.